Compare Delta Air Lines, Inc. (DAL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Mesoblast Limited — how do they compare? Delta Air Lines, Inc. trades at $90.5 (market cap $58.67B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Delta Air Lines, Inc. is far larger — about 27.2× Mesoblast Limited's market cap, and Delta Air Lines, Inc. pays a 0.87% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DAL | MESO | |
|---|---|---|
Market Cap | $58.67B | $2.16B |
Sector | Industrials | Technology |
52-Week High | $93.66 | $20.96 |
52-Week Low | $53.50 | $12.88 |
Enterprise Value | $73.99B | $2.17B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.
Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
